We are international
Donate
• health professionals TEXT SIZE   
clinical trials    back

Understanding Pomalyst®
(pomalidomide) capsules

The U.S. Food and Drug Administration (FDA) approved Pomalyst® (pomalidomide) on February 8, 2013, to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

The National Comprehensive Cancer Network (NCNN) has included pomalidomide plus dexamethasone as a salvage therapy option in patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy. For steroid-intolerant individuals, the NCNN Multiple Myeloma Panel suggests considering pomalidomide monotherapy.

08.05.13
You can view the entire document as a PDF by clicking on the icon below, or by requesting a free hard copy from the Foundation.
 

Pomalyst®, also known by its generic name, pomalidomide, is the newest in the line of anti-myeloma agents called immunomodulatory drugs, or IMiDs®, agents that can modify or regulate the functioning of the immune system.

This booklet presents information on Pomalyst and how it works, the results of clinical trials and ongoing research with Pomalyst, how and when to take Pomalyst, its possible side effects, and how to manage them.

The booklet is meant to provide you with general information only. It is not meant to replace the advice of your doctor, nurse, or other healthcare practitioners. Your healthcare team can answer specific questions related to your personal treatment plan.

 related articles